These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 36029715)
1. Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis. Bevilacqua Rolfsen Ferreira da Silva G; Pereira das Neves S; Roque Oliveira SC; Marques F; Gomes de Oliveira A; de Lima Leite F; Cerqueira JJ J Autoimmun; 2022 Oct; 132():102893. PubMed ID: 36029715 [TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis. Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542 [TBL] [Abstract][Full Text] [Related]
4. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150 [TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. Dello Russo C; Scott KA; Pirmohamed M Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Explorative Assessment of Dimethyl Fumarate-Based Biocompatible Nanolipoidal Carriers for the Management of Multiple Sclerosis. Kumar P; Sharma G; Gupta V; Kaur R; Thakur K; Malik R; Kumar A; Kaushal N; Raza K ACS Chem Neurosci; 2018 May; 9(5):1152-1158. PubMed ID: 29357233 [TBL] [Abstract][Full Text] [Related]
7. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis. de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368 [TBL] [Abstract][Full Text] [Related]
8. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J Mult Scler; 2019 Oct; 25(12):1682-1685. PubMed ID: 31208265 [TBL] [Abstract][Full Text] [Related]
9. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study. Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M Front Immunol; 2019; 10():1666. PubMed ID: 31379857 [No Abstract] [Full Text] [Related]
10. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497 [TBL] [Abstract][Full Text] [Related]
11. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Liang G; Chai J; Ng HS; Tremlett H Mult Scler Relat Disord; 2020 Nov; 46():102566. PubMed ID: 33296968 [TBL] [Abstract][Full Text] [Related]
13. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis. Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466 [TBL] [Abstract][Full Text] [Related]